text: Yo, check it out, here's the deal,
  Preliminary data reveals what's real,
  Seroconversion after SARS-CoV-2 vax,
  Might not be satisfactory in KTRs, that's the facts.
  
  But hold up, can seronegative patients shine?
  With some cellular response to draw the line,
  Against SARS-CoV-2, can they protect?
  That's the question we're here to dissect.
  
  Prospective study, 148 recipients in sight,
  Kidney or kidney-pancreas, they're in the fight,
  Testing IgM/IgG spike antibodies, so fly,
  ELISpot against N and S, let's give it a try.
  
  At baseline, 31 patients were pre-immunized,
  With IgM/IgG or ELISpot, they were baptized,
  But 117 patients showed no response at all,
  SARS-CoV-2-naïve, they stood tall.
  
  After vaccination, the game changed,
  65.0% of the naïve were rearranged,
  With humoral or cellular response in their veins,
  29.9% with IgG/IgM, the victory remains.
  
  And 35.0% with S-ELISpot positivity,
  They're building defenses with ferocity,
  Factors linked to unresponsiveness, it's true,
  Diabetes and antithymocyte treatment can skew.
  
  Side effects aligned with the pivotal trial,
  No DSAs developed, that's a smile,
  In conclusion, the mRNA-1273 vaccine,
  Brings cellular or humoral response on the scene.
  
  KTRs, listen up, almost two-thirds rejoice,
  With immunity rising, you have a choice,
  To fight off SARS-CoV-2, stand tall and bold,
  Thanks to Moderna's vaccine, the story unfolds.